Shire, the UK’s third-largest drugmaker, with head offices in Basingstoke, has agreed to pay 328 million euros ($520.7 million) for Germany’s Jerini AG to add a treatment for an illness that causes sometimes fatal swelling of tissue.Investors in Jerini will get 6.25 euros for each of their shares, 68 percent more than the Berlin-based company’s stock price today in Frankfurt. Jerini shares were suspended. The purchase will add to earnings in the second half of 2010, Shire said today in a PR Newswire statement.

Shire will get the experimental Firazyr drug, being developed to fight a life-threatening condition called hereditary angioedema.

Src. Bloomberg